Albiruni R. Abdul Razak
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (44)
Changes in peripheral T cells during AZD8853 treatment. The patient with a strong increase in proliferating T cells (left plots) started with a very low number at baseline (right plots). Whole blood samples were collected at various timepoints for analysis of numbers of peripheral T cells using flow cytometry–based immunophenotyping of circulating lymphocytes. *Baseline is the average of the screening and C1D1 predose (visit day 0). C, cycle; D, day; EOT, end of treatment; Ki67+, antigen Kiel 67 positive.
Year:
2025
Geometric mean (gSD) serum concentrations (μg/mL) of AZD8853 vs. time (semilogarithmic scale) – PK set. Vertical lines represent the geometric mean ± gSD. Geometric mean − gSD: exp (mean[log(PK Conc)] − std [log(PK Conc)]). Geometric mean + gSD: exp (mean[log(PK Conc)] + std [log(PK Conc)]). C, cycle; D, day; gSD, geometric SD; PK Conc, PK concentration.
Year:
2025
Efficacy of AZD8853 in patients with previously treated advanced/metastatic solid tumors assessed by best change from baseline in target lesion size ( A ) and ctDNA clearance ( B ). Antitumor response was measured by best percentage change in target lesion size from baseline using standard radiographic imaging. Best overall response was based on investigator assessment according to RECIST v1.1 ( A ). Clearance of ctDNA was measured from whole blood samples ( B ). a Patient had UC; all other patients had CRC. C, cycle; CRC, colorectal cancer; D, day; EOT, end of treatment; UC, urothelial carcinoma; VAF, variant allele frequency.
Year:
2025
Purpose: Growth and differentiation factor 15 (GDF15) is overexpressed in multiple solid tumors and is thought to exert immunosuppressive effects in the tumor microenvironment. AZD8853 is an anti-GDF15 mAb. Patients and Methods: This first-in-human, phase I/IIa, open-label study (NCT05397171) assessed AZD8853 monotherapy in previously treated patients with advanced/metastatic microsatellite-stable colorectal cancer and urothelial carcinoma. The primary objective was safety including dose-limiting toxicities. Secondary objectives included efficacy, pharmacokinetics, and pharmacodynamics (PD), including free serum GDF15. Exploratory objectives included biomarkers of clinical activity and effects on cancer cachexia. Results: During dose escalation, 16 patients received AZD8853 300 mg ( n = 3), 1,000 mg ( n = 6), or 3,000 mg ( n = 7) intravenously every 3 weeks; 15 patients had microsatellite-stable colorectal cancer; and one patient had urothelial carcinoma. By June 6, 2023, all patients had discontinued treatment. Thirteen (81.3%) patients had treatment-emergent adverse events (TEAE); most commonly diarrhea (31.3%), abdominal pain (31.3%), and decreased appetite (25%). Eight (50.0%) patients had grade ≥3 TEAEs, and six (37.5%) had serious TEAEs, none treatment related. There were no dose-limiting toxicities. The best response per RECIST v1.1 was stable disease in five (31.3%) patients and disease progression in 11 (68.8%) patients. AZD8853 showed linear pharmacokinetics with a half-life of 5 to 10 days, supporting every 3 weeks dosing. AZD8853 suppression of GDF15 was transient. There was no evidence of ctDNA clearance or dose-dependent changes in peripheral T cells. Changes in body weight showed no apparent trends. Conclusions: AZD8853 was well tolerated; however, no objective responses or PD effects were seen, and GDF15 suppression was not sustained. The study was terminated after dose escalation. Significance: GDF15 is upregulated in the tumor microenvironment and suppresses antitumor immune responses. In this first-in-human trial, the anti-GDF15 antibody AZD8853 was well tolerated in previously treated patients with advanced/metastatic solid tumors, but no objective responses or PD effects were seen and GDF15 suppression was not sustained.
Year:
2025
Purpose: Growth and differentiation factor 15 (GDF15) is overexpressed in multiple solid tumors and is thought to exert immunosuppressive effects in the tumor microenvironment. AZD8853 is an anti-GDF15 mAb. Patients and Methods: This first-in-human, phase I/IIa, open-label study (NCT05397171) assessed AZD8853 monotherapy in previously treated patients with advanced/metastatic microsatellite-stable colorectal cancer and urothelial carcinoma. The primary objective was safety including dose-limiting toxicities. Secondary objectives included efficacy, pharmacokinetics, and pharmacodynamics (PD), including free serum GDF15. Exploratory objectives included biomarkers of clinical activity and effects on cancer cachexia. Results: During dose escalation, 16 patients received AZD8853 300 mg (n = 3), 1,000 mg (n = 6), or 3,000 mg (n = 7) intravenously every 3 weeks; 15 patients had microsatellite-stable colorectal cancer; and one patient had urothelial carcinoma. By June 6, 2023, all patients had discontinued treatment. Thirteen (81.3%) patients had treatment-emergent adverse events (TEAE); most commonly diarrhea (31.3%), abdominal pain (31.3%), and decreased appetite (25%). Eight (50.0%) patients had grade ≥3 TEAEs, and six (37.5%) had serious TEAEs, none treatment related. There were no dose-limiting toxicities. The best response per RECIST v1.1 was stable disease in five (31.3%) patients and disease progression in 11 (68.8%) patients. AZD8853 showed linear pharmacokinetics with a half-life of 5 to 10 days, supporting every 3 weeks dosing. AZD8853 suppression of GDF15 was transient. There was no evidence of ctDNA clearance or dose-dependent changes in peripheral T cells. Changes in body weight showed no apparent trends. Conclusions: AZD8853 was well tolerated; however, no objective responses or PD effects were seen, and GDF15 suppression was not sustained. The study was terminated after dose escalation. Significance: GDF15 is upregulated in the tumor microenvironment and suppresses antitumor immune responses. In this first-in-human trial, the anti-GDF15 antibody AZD8853 was well tolerated in previously treated patients with advanced/metastatic solid tumors, but no objective responses or PD effects were seen and GDF15 suppression was not sustained.
Year:
2025
Purpose: In this phase 1 portion of a first-in-human phase 1/2a study (NCT05199272), 23ME-00610 was evaluated in participants with advanced solid malignancies to determine its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). Exploratory biomarkers were evaluated to examine potential correlates of efficacy and safety. Patients and Methods: Eligible participants (≥18 years) were administered 23ME-00610 intravenously every 3 weeks (Q3W) using an accelerated titration design followed by a traditional 3 + 3 design, with an initial dose level of 2 mg. Results: Twenty-eight participants were enrolled across seven cohorts and received a median of four cycles of 23ME-00610. No treatment-related serious adverse events (AE) were observed, and the maximum tolerated dose was not reached. Overall, the PK of 23ME-00610 was linear and dose proportional for doses ≥60 mg, with a median terminal half-life of 13 days at 1,400 mg. Peripheral saturation of CD200R1 was observed for doses ≥60 mg. Immune-related AEs, including rash, pruritus, and hypothyroidism, were predicted by phenome-wide association studies and observed for doses ≥60 mg. A confirmed partial response was observed in a participant with well-differentiated pancreatic neuroendocrine cancer whose tumor was among those with the highest tumor CD200 expression. Conclusions: 23ME-00610 has mild-to-moderate on-target AEs and PK/PD consistent with tumor target saturation and dosing every 3 weeks. The trend for clinical benefit in participants with tumor CD200 expression suggests that 23ME-00610 inhibits CD200R1 signaling and may reverse CD200-mediated immune evasion. Based on PK/PD, safety, and preliminary antitumor activity, 1,400 mg Q3W was selected as the dose for further study. Significance: Genome-wide association studies (GWAS) of the 23andMe genetic database identified CD200R1 as a promising therapeutic target for cancer. This phase 1 study of 23ME-00610, a CD200R1 antagonist IgG1, showed acceptable safety and tolerability, PK supporting Q3W dosing, and PD and preliminary clinical activity supporting an initial recommended phase 2 dose of 1,400 mg.
Year:
2025
Patients were scanned and assessed by RECIST v1.1 approximately every 8 weeks. A, Swimmer plot showing the treatment duration and BOR for enrolled patients across all dose levels. BOR for PD (star), SD (circle), and PR (square) is shown. Additional annotations for first PD or death (upward gray triangle), the last non-PD assessment (X mark), and treatment ongoing (right-facing black triangle) are included. Each color represents the cohort/dose level. Eight patients that initially received doses ≤600 mg had their dose escalated during treatment. B, Waterfall plot showing the %change in baseline target lesion SoD and BOR for enrolled patients across all dose levels. Each color represents the cohort/dose level initially received. Best response is noted for PD (circle), SD (diamond), and PR (square). One patient remains on treatment as of the data cut date is noted with a black triangle. N = 2 patients were not evaluable due to missing postbaseline assessment; thus, only N = 26 patients with BOR data per RECIST v1.1. C, Baseline and week 64 scans and target lesion diameter summary for the patient with a well-differentiated pancreatic neuroendocrine tumor with confirmed PR. Data as of October 2, 2024. SoD, sum of diametres.
Year:
2025
CD200 and CD200R1 expression in participant tumors. A, Representative photomicrographs of H&E, CD200, and CD200R1 IHC-stained sections of tumor from a patient with a well-differentiated neuroendocrine tumor (patient in Fig. 2C ) whose target lesions shrank 39% from baseline assessments. B, Distribution of CD200 H-scores and CD200R1-positive immune cells (% positive cells) at baseline. Pink data points present the CD200 H-score and CD200R1 %–positive immune cell value for the patient tumor shown in A [CD200 H-score of 155; CD200R1 %–positive immune cells of C, Baseline CD200 tumor cell membrane staining intensity and frequency (%) for 19 patients with evaluable archival tumor tissue that received pharmacologic active doses of 23ME-00610 (≥60 mg) and sorted by PR, SD, or PD. ASPS, alveolar soft part sarcoma; CESC, cervical squamous cell carcinoma; ccSCA, clear cell chondrosarcoma; H&E, hematoxylin and eosin; LSA, leiomyosarcoma; NSCLC, non–small cell lung cancer; SKCM, cutaneous melanoma; THCA, papillary thyroid carcinoma.
Year:
2025
Single-dose serum PK and peripheral target engagement for 23ME-00610 in patients with cancer by dose level. Sample size for participants with evaluable data by dose cohorts: 1,400 mg ( N = 8), 600 mg ( N = 8), 200 mg ( N = 3),60 mg ( N = 4), 20 mg ( N = 3), 6 mg ( N = 1), and 2 mg ( N = 1). A, Geometric mean and geometric SD for cycle 1 serum 23ME-00610 concentration–time data by dose level. Below limit of quantitation (BLQ) values were set to missing, and data were plotted only if more than half of the evaluable data was quantifiable [greater than the lower limit of quantitation (LLOQ)] and not missing. EC 90 in tumor PK target (dotted reference line) based on in vitro tumor-killing assay and 10% tumor-to-serum partition. B, Median RO by dose level for cycle 1. The RO assay is qualitative and measures 23ME-00610 bound to the target receptor CD200R1 on the target cell of interest. At least 60% RO (shaded in green) is considered saturated, in which less than 60% RO is considered not saturated. C, Median-free soluble CD200R1 by dose level from cycle 1 day 1 predose to cycle 4 day 1 predose (63 study days). The assay lower limit of detection (following a 20-fold minimum required dilution) is 312 pg/mL (dotted reference line). BLQ values were plotted at the LLOQ. All patients for dose levels ≥60 mg were BLQ at day 21 and day 63. D, Median total soluble CD200R1 (sum of free soluble CD200R1 and 23ME-00610–bound soluble CD200R1) by dose level from cycle 1 day 1 predose to cycle 4 day 1 predose (63 study days). The assay lower limit of detection (following a 20-fold minimum required dilution) is 312 pg/mL (dotted reference line).
Year:
2025
Purpose: Non-inflamed (cold) tumors such as leiomyosarcoma do not benefit from immune checkpoint blockade (ICB) monotherapy. Combining ICB with angiogenesis or PARP inhibitors may increase tumor immunogenicity by altering the immune cell composition of the tumor microenvironment (TME). The DAPPER phase II study evaluated the safety, immunologic, and clinical activity of ICB-based combinations in pretreated patients with leiomyosarcoma. Patients and Methods: Patients were randomized to receive durvalumab 1,500 mg IV every 4 weeks with either olaparib 300 mg twice a day orally (Arm A) or cediranib 20 mg every day orally 5 days/week (Arm B) until unacceptable toxicity or disease progression. Paired tumor biopsies, serial radiologic assessments and stool collections were performed. Primary endpoints were safety and immune cell changes in the TME. Objective responses and survival were correlated with transcriptomic, radiomic, and microbiome parameters. Results: Among 30 heavily pretreated patients (15 on each arm), grade ≥ 3 toxicity occurred in 3 (20%) and 2 (13%) on Arms A and B, respectively. On Arm A, 1 patient achieved partial response (PR) with increase in CD8 T cells and macrophages in the TME during treatment, while 4 had stable disease (SD) ≥ 6 months. No patients on Arm B achieved PR or SD ≥ 6 months. Transcriptome analysis showed that baseline M1-macrophage and B-cell activity were associated with overall survival. Conclusions: Durvalumab plus olaparib increased immune cell infiltration of TME with clinical benefit in some patients with leiomyosarcoma. Baseline M1-macrophage and B-cell activity may identify patients with leiomyosarcoma with favorable outcomes on immunotherapy and should be further evaluated.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (27)
Shivaani Kummar
Oregon Health & Science University
Aaron R. Hansen
Medical Oncologist
University Health Network
Benjamin Haibe-Kains
University of Toronto
Benedito A. Carneiro
-
Javier Martín-Broto
-
Nicholas M. Bernthal
University of California, Los Angeles
Breelyn A. Wilky
Associate Professor
University of Colorado Anschutz Medical Campus
Thierry Alcindor
McGill University Health Centre
Anna Spreafico
University Health Network
Lara Davis
Fred Hutch Cancer Center
Ana Vivancos
Principal Investigator
Vall d'Hebron Institute of Oncology
Marcus Butler
University Health Network
Pamela S. Ohashi
University of Toronto
Scott A. Laurie
University of Ottawa
Philip Awadalla
Professor of Molecular Genetics and Director
University of Oxford
Lillian L. Siu
University Health Network
Patricia LoRusso
Yale University
Bryan Coburn
University Health Network
Philippe L. Bedard
University Health Network
Michiel A. J. van de Sande
Princess Maxima Center
Abha A. Gupta
Hospital for Sick Children
Elena Garralda
Director
-
Hans Gelderblom
Prof.dr
Leiden University Medical Center
Piotr Rutkowski
Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie
Trevor J. Pugh
Professor
University Health Network
Ping Luo
Assistant Professor
Algoma University
BARTLOMIEJ SZOSTAKOWSKI
Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie
Make your next move.
Prepare your application
Review drafts before you send them.